These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 35132063)

  • 61. Update of antibody-drug conjugates for hematological malignancies.
    Sun W; Hu S; Wang X
    Curr Opin Oncol; 2024 Sep; 36(5):430-436. PubMed ID: 39007226
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors.
    Liu J; Zhu J
    Int Immunopharmacol; 2024 Sep; 138():112609. PubMed ID: 38971103
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer].
    Zhu Y; Wang Z
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):468-476. PubMed ID: 35899443
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting cancer with antibody-drug conjugates: Promises and challenges.
    Dean AQ; Luo S; Twomey JD; Zhang B
    MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bispecific and multispecific antibodies in oncology: opportunities and challenges.
    Goebeler ME; Stuhler G; Bargou R
    Nat Rev Clin Oncol; 2024 Jul; 21(7):539-560. PubMed ID: 38822215
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Danish bispecifics meet ADCs.
    Nat Biotechnol; 2020 Jul; 38(7):774. PubMed ID: 32641846
    [No Abstract]   [Full Text] [Related]  

  • 70. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
    Pondé N; Aftimos P; Piccart M
    Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunotherapy in aggressive B-cell lymphomas.
    Jacobson CA; Armand P
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development and clinical application of bispecific antibody in the treatment of colorectal cancer.
    Balibegloo M; Rezaei N
    Expert Rev Clin Immunol; 2020 Jul; 16(7):689-709. PubMed ID: 32536227
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted Therapy With Immunoconjugates for Multiple Myeloma.
    Bruins WSC; Zweegman S; Mutis T; van de Donk NWCJ
    Front Immunol; 2020; 11():1155. PubMed ID: 32636838
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    Parren PW; Burton DR; Bradbury A; Huston JS; Carter PJ; Veldman T; Chester KA; Larrick JW; Alfenito MR; Scott JK; Weiner LM; Adams GP; Reichert JM
    MAbs; 2015; 7(6):981-8. PubMed ID: 26421752
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
    Derby L; Czuczman MS
    Future Oncol; 2011 Aug; 7(8):963-79. PubMed ID: 21823892
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibody drug conjugates.
    Teicher BA
    Curr Opin Oncol; 2014 Sep; 26(5):476-83. PubMed ID: 25024051
    [TBL] [Abstract][Full Text] [Related]  

  • 80. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
    Wu Z; Cheung NV
    Pharmacol Ther; 2018 Feb; 182():161-175. PubMed ID: 28834699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.